Ashish Bajel, MBBS, FRACP, FRCPA, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia, discusses the challenge of treating older patients with acute myeloid leukemia (AML) with venetoclax and azacitidine due to the occurrence of cytopenias associated with long-term treatment. Dr Bajel highlights two possible solutions to this dilemma: personalizing and optimizing venetoclax plus azacitidine treatment and investigating the effect of adding a third agent to the doublet to enhance efficacy while limiting toxicities. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть